Simple blood draw could guide liver cancer therapy

NCT ID NCT07378709

Recruiting now Knowledge-focused Sponsor: University of Belgrade Source: ClinicalTrials.gov ↗

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 2 times

Summary

This observational study is looking at whether certain substances in the blood can help predict and monitor how liver cancer responds to a treatment called TACE. Researchers will collect blood samples from 15 adult patients before and after TACE and compare them with standard imaging scans. The goal is to see if blood markers can give early clues about treatment success, potentially reducing the need for extra scans.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

What this could lead to: If successful, this could lead to a simple blood test to help doctors predict and monitor how well liver cancer responds to TACE treatment.
What could go wrong: This is a very small pilot study with only 15 participants, so results may not apply to everyone. It is observational, meaning it does not test a new treatment.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for HEPATOCELLULAR CARCINOMA (HCC) are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

hepatocellular carcinoma liver and intrahepatic bile duct neoplasm Liver Neoplasms

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

HEPATOCELLULAR CARCINOMA (HCC) LIVER NEOPLASMS

Contacts and locations

Locations

KBC Bežanijska kosa
RECRUITING

Belgrade, Serbia

More trials for these conditions

Other studies related to the condition(s) this trial covers.